GMF Capital
VC Fund
New York, United States
GMF Capital is a private investment vehicle that engages in private equity and alternative investments across a broad range of asset classes including real estate, healthcare, and structured credit. The management platform's investment approach is driven by its experience and a proprietary network of relationships. It generates outsizerisk-adjusted returns through cash-flowing investments characterized by liquidity and limited exposure to cyclical volatility.GMF Capital began its operations in 2013 and is operating in New York.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries GMF Capital invests in
Stages GMF Capital invests in
Countries GMF Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Post-IPO Equity
- $18M–$75M
Investment Focus
Industry
- FinTech 2 (29%)
- Apps 1 (14%)
- Gaming 1 (14%)
- Mobile 1 (14%)
- Bitcoin 1 (14%)
Stage
- Seed 2 (29%)
- Post-IPO Equity 2 (29%)
- Series A 1 (14%)
- Funding Round 1 (14%)
- Private Equity 1 (14%)
Country
- Switzerland 2 (29%)
- United States 2 (29%)
- Israel 1 (14%)
- United Kingdom 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gary Fegel
Founder
|
Founder | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
sMiles
|
sMiles is a platform for micropayments and micro-incentives in Bitcoin. | Seed / Feb 10, 2022 | |
Qredo
|
Qredo is a platform that provides secure and fast movement of digital assets.Qredo powers institutional traders to secure and accelerate the movement of digital assets 24/7 on an open protocol.Qredo eliminates the operational and security burden of wallet key management and the cyber-threats that result from trading operations, storage, andtransfer of digital assets | $80M / Series A / Feb 04, 2022 | |
Pardes Biosciences
|
Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner. | $75M / Post-IPO Equity / Dec 27, 2021 | |
My Sky
|
My Sky is an independent expert in private aviation that empowers jet owners across the globe by providing them with a revolutionary financial controlling and benchmarking tool to optimize time and money spent on their asset. My Sky’s innovative IT platform collects, digitizes, verifies, analyses and stores all financial information and allowsinstant access to the information that matters. The concept of My Sky was developed in 2014 by two entrepreneurs active in private banking and private aviation. Since its public launch in August 2015, My Sky has convinced an exponential number of business aircraft owners in Europe and CIS. The company is headquartered in Switzerland and currently employs over 80 experts, including in-house auditors, analysts and IT specialists. My Sky offers Swiss standards in terms of efficiency, system security and data confidentiality. It is privately owned and totally independent, which prevents it from being influenced by any market player and allows total commitment to its mission: to revolutionize jet ownership through technology and expertise. My Sky has won a number of prestigious awards, including “Company of the Year (Aviation)” from ACQ5 Global Awards 2017, Gold Stevie® Award as “Startup of the Year – Business Services Industries” and Silver Stevie® Award as “Tech Startup of the Year” in 2017 International Business Awards, 2016 Sapphire Pegasus Business Aviation Award for Innovation. My Sky covers the EMEA area and is expanding its presence globally, becoming a key player in the business aviation industry. It is a EBAA and AEROSUISSE member. | $5M / Jun 06, 2020 | |
|
My Sky
|
My Sky is an independent expert in private aviation that empowers jet owners across the globe by providing them with a revolutionary financial controlling and benchmarking tool to optimize time and money spent on their asset. My Sky’s innovative IT platform collects, digitizes, verifies, analyses and stores all financial information and allowsinstant access to the information that matters. The concept of My Sky was developed in 2014 by two entrepreneurs active in private banking and private aviation. Since its public launch in August 2015, My Sky has convinced an exponential number of business aircraft owners in Europe and CIS. The company is headquartered in Switzerland and currently employs over 80 experts, including in-house auditors, analysts and IT specialists. My Sky offers Swiss standards in terms of efficiency, system security and data confidentiality. It is privately owned and totally independent, which prevents it from being influenced by any market player and allows total commitment to its mission: to revolutionize jet ownership through technology and expertise. My Sky has won a number of prestigious awards, including “Company of the Year (Aviation)” from ACQ5 Global Awards 2017, Gold Stevie® Award as “Startup of the Year – Business Services Industries” and Silver Stevie® Award as “Tech Startup of the Year” in 2017 International Business Awards, 2016 Sapphire Pegasus Business Aviation Award for Innovation. My Sky covers the EMEA area and is expanding its presence globally, becoming a key player in the business aviation industry. It is a EBAA and AEROSUISSE member. | $5M / Private Equity / Jun 06, 2020 | |
InterCure
|
InterCure is a medical device company that has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases.The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class ofnon-drug treatments for two of the most widespread and costly disease states in the healthcare industry: hypertension and heart failure.InterCure’s first market-ready product, RESPeRATE, is the only FDA-cleared, medical device clinically proven to lower high blood pressure with no side effects.InterCure's heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched when it completes the regulatory approval process.With its outstanding management team, the board of directors and a world-class Scientific Advisory Board, Intercure is poised to become the market leader in patient-focused medical devices that provide non-drug, no-side-effect treatment for some of the world's most prevalent and costly chronic conditions.InterCure was founded in 1994 and is headquartered in Ra'anana, Israel. | $17.5M / Post-IPO Equity / Nov 01, 2018 | |
TouchSpin Gaming AG
|
TouchSpin Gaming has created a patented, multiplayer slot platform called TouchSpin Casino. Our first release on the platform is a social casino game called Texas Reels. This is a social, multiplayer slot game for the free to play casual games audience and hybridizes poker and slots.Texas Reels is based on our patented mutliplayer slotmechanic, that let’s you bet against other players sitting with you at the table. All bets go into the pot, like poker, and the winner takes all.TouchSpin Gaming is re-imagining the social casino platform. With revolutionary new slots interfaces, fast and easy game play, powerups and complete meta-game, we’ve created a thrilling new casino game experience, especially for Millienials.The TouchSpin Casino team is managed by technology and gaming professionals who are passionate about creating the next big thing in the casino slot experience. We have put our many years of industry experience into the development of what we believe is the multiplayer casino platform that will redefine the slots category. | $400K / Seed / Jan 05, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does GMF Capital invest in?
GMF Capital invests primarily in FinTech, Apps and Gaming startups, most often at Seed and Post-IPO Equity stage. Most of the 7 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is GMF Capital's check size?
GMF Capital typically joins rounds of $18M–$75M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GMF Capital participates in.
How do I contact GMF Capital?
Public channels for GMF Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GMF Capital?
The team at GMF Capital includes Gary Fegel (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
